Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

FibroBiologics, Inc. - Common Stock (NQ:FBLG)

0.9696 +0.0396 (+4.26%)
Delayed Quote Updated: 9:42 AM EDT, Oct 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about FibroBiologics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Verde Resources (OTCQB: VRDR) Reframes Nasdaq Uplisting Strategy With Commercial Growth in Focus
Via AB Newswire
News headline image
Nova Minerals and FibroBiologics Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV
From RedChip Companies, Inc. (Media Suite)
Via ACCESS Newswire
News headline image
Join FibroBiologics' Live Investor Webinar: Advancing a Fibroblast-Based Cell Therapy Platform Across Multiple High-Value Indications
Learn how FibroBiologics is developing an off-the-shelf therapeutic platform designed to harness the regenerative and immune-modulating properties of fibroblasts Management to discuss the ongoing Phase... 
From RedChip Companies, Inc. (Media Suite)
Via ACCESS Newswire
News headline image
FibroBiologics Receives Notice of Allowance for U.S. Patent Covering Topical Fibroblast Spheroid Therapy for Wound Healing
Allowed claims directly support the Company’s ongoing Phase 1/2 clinical trial of CYWC628 in patients with diabetic foot ulcers 
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Advances Patient Dosing for Phase 1/2 Clinical Trial of CYWC628 for the Treatment of Diabetic Foot Ulcers
Company continues to advance CYWC628 manufacturing with second GMP drug product run released for shipment to Australia and a third run nearing completion 
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Announces First Patients Dosed in Phase 1/2 Clinical Trial Evaluating CYWC628 for the Treatment of Diabetic Foot Ulcers
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
EXCLUSIVE: FibroBiologics Doses First Patients In Diabetic Foot Ulcers Clinical Trial ↗
FibroBiologics Inc. (NASDAQ: FBLG) reports enrolling first patients in its Phase 1/2 trial for CYWC628, a fibroblast-based therapy targeting diabetic foot ulcers. 
Via Benzinga
News headline image
FibroBiologics Presents Preclinical Data Demonstrating Durable Immunomodulation in Psoriasis at the Society for Investigative Dermatology 2026 Annual Meeting
In animal studies, human dermal fibroblast spheroids reduce disease severity, prevent relapse, and suppress key inflammatory pathways associated with chronic psoriatic disease 
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Files Patent Application for Oral Administration of Fibroblast Therapeutics
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Advancing Development of a Fibroblast Treatment for Hantavirus
Will Apply Existing Preclinical Findings in Reducing Severe Immune-Mediated Lung Failure to Potential Emerging Global Crisis 
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics CEO Issues Letter to Shareholders
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Reports Preclinical Data Showing Fibroblast Spheroids May Actively Reprogram the Burn Wound Environment to Drive Healing and Reduce Scarring
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Announces Release of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Reports Q1 2026 Financial Results and Provides Corporate Update
On track for first patient dosed in phase 1/2 clinical trial evaluating CYWC628 in diabetic foot ulcers in Q2 of 2026 
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Announces Poster Presentation at the Society for Investigative Dermatology Annual Meeting 2026
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Compliant with All Nasdaq Listing Requirements
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Presents Novel Thymus Organoid Platform to Combat Age-Related Immune Decline at Keystone Symposia on Aging and Immunity
Preclinical models demonstrate potential to restore thymic function lost with aging reducing susceptibility to cancer, autoimmune diseases, infections, and reduced vaccine efficacy 
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Announces Closing of $3 Million Public Offering
From FibroBiologics, Inc.
Via GlobeNewswire
Which stocks are moving before the opening bell on Wednesday? ↗
Via Chartmill
News headline image
FibroBiologics Announces Pricing of $3 Million Public Offering
From FibroBiologics, Inc.
Via GlobeNewswire
Top movers in Tuesday's after hours session ↗
Via Chartmill
News headline image
FibroBiologics Announces Successful Manufacturing of CYWC628 Drug Product to Support Upcoming Diabetic Foot Ulcer Clinical Trial
From FibroBiologics, Inc.
Via GlobeNewswire
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
Via Chartmill
Which stocks are experiencing notable movement on Tuesday? ↗
Via Chartmill
The market is filled with gapping stocks in Tuesday's session. ↗
Via Chartmill
Stay updated with the stocks that are on the move in today's after-hours session. ↗
Via Chartmill
News headline image
FibroBiologics Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Bid Price Requirement
Reverse Split Expected to Take Effect March 30, 2026 
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
The $45 Billion Cell Therapy Boom Just Hit a Manufacturing Milestone Most Investors Haven’t Noticed
AVAI, FBLG, FATE, MESO, and LGVN as Regenerative Medicine Moves From Lab to GMP Manufacturing Facilities 
From USA News Group
Via GlobeNewswire
News headline image
FibroBiologics Announces Advances in Burn Treatment Using Proprietary Fibroblast Spheroid Technology
From FibroBiologics, Inc.
Via GlobeNewswire
News headline image
FibroBiologics Completes Site Onboarding for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers
From FibroBiologics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.